Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Teva
Sort By
Newest First
1 / 1
1 / 1
Recall
Teva Pharmaceuticals USA, Inc. Initiates Voluntary Nationwide Recall of Metformin Hydrochloride
Teva Pharmaceutical Industries
PR-M06-20-NI-025-1496
Jun 18, 2020
EpiPen
Teva Announces Availability of a Generic Equivalent of EpiPen Jr in the United States
Teva Pharmaceutical Industries
PR-M08-19-NI-069
Aug 23, 2019
M&A
FLAMMA Acquires Teva’s Philadelphia cGMP Facility Marking Entry into the US Marketplace with Labs & Pilot Plant
Nice Insight
PR-M07-19-NI-013
Jul 02, 2019
Generics
Teva Announces Launch of a Generic Version of Tarceva® (erlotinib) Tablets in the United States
Teva Pharmaceutical Industries
PR-M05-19-NI-045
May 15, 2019
Clinical Development
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
Teva Pharmaceutical Industries
PR-M04-19-NI-077
Apr 24, 2019
Generics
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
Teva Pharmaceutical Industries
PR-M04-19-NI-072
Apr 23, 2019
Generics
Teva Announces Launch of ALYQ™ (Tadalafil Tablets USP), a Generic Version of ADCIRCA® in the United States
Teva Pharmaceutical Industries
PR-M02-19-NI-014
Feb 07, 2019
Drug Development
EMA Committee Recommends Approval of Teva’s Anti-CGRP Treatment for Migraines
Emilie Branch
Pharma's Almanac
PAO-M02-19-NI-003
Feb 06, 2019
FDA
Another Biosimilar Gets Nod from Independent FDA Panel
Nice Insight
PAO-M10-18-NI-018
Oct 22, 2018
Study Results
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical Industries
PR-M09-18-NI-059
Sep 20, 2018
Study Results
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical Industries
PR-M09-18-NI-051
Sep 18, 2018
Announcement
Governor Murphy Announces Teva Pharmaceuticals to Locate US Headquarters in New Jersey
Teva Pharmaceutical Industries
PR-M07-18-NI-025
Jul 09, 2018
Drug Discovery
TEVA Hopes to Launch New Migraine Drug Immediately After PDUFA Date
Guy Tiene
Nice Insight
PAO-M05-18-NI-020
May 29, 2018
Clinical Data
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL
Teva Pharmaceutical Industries
PR-M05-18-NI-013
May 02, 2018
Generic
Teva Announces the Launch of a Generic Version of Lialda® in the United States
Teva Pharmaceutical Industries
PR-M03-18-NI-100-4488
Mar 28, 2018
Drug Development
Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headaches
Sosei
PR-M03-18-NI-054
Mar 15, 2018
Inhalation
Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol
Teva Pharmaceutical Industries
PR-M02-18-NI-53
Feb 15, 2018
Generics
Teva Announces Launch of a Generic Version of Syprine® in the United States
Teva Pharmaceutical Industries
PR-M02-18-NI-050
Feb 14, 2018
FDA Approval
Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia
Teva Pharmaceutical Industries
PR-M01-18-NI-053
Jan 18, 2018
Drug Development
Teva Announces Sale of PARAGARD® (intrauterine copper contraceptive) to CooperSurgical
Teva Pharmaceutical Industries
PR-M08-17-NI-014
Sep 12, 2017
